SAB Biotherapeutics
SABS
41 hedge funds and large institutions have $93.8M invested in SAB Biotherapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
11% more funds holding
Funds holding: 37 → 41 (+4)
0% more capital invested
Capital invested by funds: $93.6M → $93.8M (+$131K)
0.06% less ownership
Funds ownership: 6.36% → 6.29% (-0.06%)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$3.09M |
| 2 |
DKCM
Davidson Kempner Capital Management
New York
|
+$1.99M |
| 3 |
FTCM
Fir Tree Capital Management
New York
|
+$1.99M |
| 4 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$1.84M |
| 5 |
Millennium Management
New York
|
+$1.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
-$5.3M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$3.98M |
| 3 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$2.47M |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$1.35M |
| 5 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$997K |
SABS Hedge Fund Activity: Q3 2021 in Review
41 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q3 2021, worth a combined $93.8M — up 0.14% from $93.6M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SABS positions and 5 closed out — a net gain of 4 holders — while 9 added to existing stakes and 10 trimmed.
The largest buyer was Magnetar Financial, adding an estimated $3.09M. The largest seller was Glazer Capital LLC, cutting an estimated $5.3M.
- 41 institutional investors held SAB Biotherapeutics (SABS) as of Q3 2021, up from 37 in Q2 2021.
- Funds reported $93.8M of SAB Biotherapeutics stock for Q3 2021, up 0.14% quarter-over-quarter.
- 9 funds opened new SAB Biotherapeutics positions in Q3 2021 and 5 closed out, a net change of +4 holders.
- The largest SAB Biotherapeutics buyer in Q3 2021 was Magnetar Financial, an estimated $3.09M added.
- The largest SAB Biotherapeutics seller in Q3 2021 was Glazer Capital LLC, an estimated $5.3M sold.
Based on aggregated 13F filings for Q3 2021.